Comparison of 68Ga-DOTATATE and 18F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 1, 2010, Pages 49-57

  Conry, Brendon G ^b   Papathanasiou, Nikolaos D ^a   Prakash, Vineet ^a   Kayani, Irfan ^a   Caplin, Martyn ^c   Mahmood, Shahid ^d   Bomanji, Jamshed B ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b Pembury Hospital   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d Singapore PET and Cardiac Imaging Centre   (Singapore)

Author keywords

18F fluorodeoxyglucose; 68Ga DOTATATE; Medullary thyroid carcinoma; Positron emission tomography

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[1 DEXTRO PHENYLALANINE, 3 TYROSINE]; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTATE[1 DEXTRO PHENYLALANINE, 3 TYROSINE] GALLIUM GA 68; CALCITONIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE; CALCITONIN BLOOD LEVEL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DISTRIBUTION; FEMALE; HUMAN; ISOTOPE LABELING; LIVER; LUNG; MALE; MEDIASTINUM; RECURRENT CANCER; THYROID GLAND; THYROID MEDULLARY CARCINOMA; TISSUE DISTRIBUTION;

ADULT; AGED; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; THYROID GLAND; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 72949103236     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1204-z     Document Type: Article

References (28)

1. DW Ball 2007 Medullary thyroid cancer: monitoring and therapy Endocrinol Metab Clin North Am 36 823 837 10.1016/j.ecl.2007.04.001 1:CAS:528: DC%2BD2sXhtFCgsrjP 17673130 viii (Pubitemid 47126253)
2. C Scollo E Baudin JP Travagli B Caillou N Bellon S Leboulleux, et al. 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer J Clin Endocrinol Metab 88 2070 2075 10.1210/jc.2002-021713 1:CAS:528:DC%2BD3sXjs1OktLs%3D 12727956 (Pubitemid 36549878)
3. JF Moley MK DeBenedetti 1999 Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection Ann Surg 229 880 887 10.1097/00000658-199906000-00016 1:STN:280:DyaK1M3ptVGksw%3D%3D 10363903 discussion 887-888 (Pubitemid 30191739)
4. V Rufini G Treglia G Perotti L Leccisotti ML Calcagni D Rubello 2008 Role of PET in medullary thyroid carcinoma Minerva Endocrinol 33 67 73 1:STN:280:DC%2BD1c3lt1Wjsw%3D%3D 18388854
5. R Elisei V Bottici F Luchetti G Di Coscio C Romei L Grasso, et al. 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders J Clin Endocrinol Metab 89 163 168 10.1210/jc.2003-030550 1:CAS:528:DC%2BD2cXmvFeqsA%3D%3D 14715844 (Pubitemid 38183876)
6. V Rufini P Castaldi G Treglia G Perotti MD Gross A Al-Nahhas, et al. 2008 Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma Biomed Pharmacother 62 139 146 10.1016/j.biopha.2007.07.011 1:CAS:528:DC%2BD1cXjs1Wgsrc%3D 17892924
7. E Kebebew PH Ituarte AE Siperstein QY Duh OH Clark 2000 Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems Cancer 88 1139 1148 10.1002/(SICI)1097- 0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z 1:STN:280: DC%2BD3c7msVelsA%3D%3D 10699905 (Pubitemid 30127676)
8. C Jiménez MI Hu RF Gagel 2008 Management of medullary thyroid carcinoma Endocrinol Metab Clin North Am 37 481 496 10.1016/j.ecl.2008.03.001 18502338 x-xi (Pubitemid 351698091)
9. JW de Groot TP Links PL Jager T Kahraman JT Plukker 2004 Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer Ann Surg Oncol 11 786 794 10.1245/ASO.2004.10.015 15289241 (Pubitemid 40486694)
10. KP Koopmans JW de Groot JT Plukker EG de Vries IP Kema WJ Sluiter, et al. 2008 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation J Nucl Med 49 524 531 10.2967/jnumed.107.047720 1:CAS:528:DC%2BD1cXltl2gtLs%3D 18375923
11. GK von Schulthess HC Steinert TF Hany 2006 Integrated PET/CT: current applications and future directions Radiology 238 405 422 10.1148/radiol. 2382041977 (Pubitemid 43134354)
12. SC Ong H Schöder SG Patel IM Tabangay-Lim I Doddamane M Gönen, et al. 2007 Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels J Nucl Med 48 501 507 10.2967/jnumed.106.036681 1:CAS:528:DC%2BD2sXhtVert7jE 17401085 (Pubitemid 47571403)
13. MC Zatelli D Piccin F Tagliati A Bottoni A Luchin C Vignali, et al. 2006 Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives J Clin Endocrinol Metab 91 2218 2224 10.1210/jc.2006-0334 1:CAS:528:DC%2BD28XlvVCgsb0%3D 16569735 (Pubitemid 43855009)
14. E Mato X Matias-Guiu A Chico SM Webb R Cabezas L Berná, et al. 1998 Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma J Clin Endocrinol Metab 83 2417 2420 10.1210/jc.83.7.2417 1:CAS:528:DyaK1cXksVSisrw%3D 9661621 (Pubitemid 28503040)
15. M Papotti U Kumar M Volante C Pecchioni YC Patel 2001 Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid Clin Endocrinol 54 641 649 10.1046/j.1365-2265.2001.01175.x 1:CAS:528:DC%2BD3MXks1Kgsb4%3D (Pubitemid 34208908)
16. JC Reubi JC Schar B Waser S Wenger A Heppeler JS Schmitt, et al. 2000 Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 273 282 10.1007/s002590050034 1:CAS:528:DC%2BD3cXhsVWns7w%3D 10774879
17. I Kayani JB Bomanji A Groves G Conway S Gacinovic T Win, et al. 2008 Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG Cancer 112 2447 2455 10.1002/cncr.23469 18383518
18. V Rufini ML Calcagni RP Baum 2006 Imaging of neuroendocrine tumors Semin Nucl Med 36 228 247 10.1053/j.semnuclmed.2006.03.007 16762613 (Pubitemid 43817847)
19. G Costante C Durante Z Francis M Schlumberger S Filetti 2009 Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls Nat Clin Pract Endocrinol Metab 5 35 44 10.1038/ncpendmet1023 1:CAS:528:DC%2BD1cXhsV2itbvN 19079272
20. TM Behr W Becker 1999 Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions? Eur J Nucl Med 26 70 71 1:STN:280: DyaK1M7ls1SmsQ%3D%3D 10048954
21. AL Giraudet D Vanel S Leboulleux A Auperin C Dromain L Chami, et al. 2007 Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels J Clin Endocrinol Metab 92 4185 4190 10.1210/jc.2007-1211 1:CAS:528: DC%2BD2sXhtlartbzP 17726071 (Pubitemid 350074730)
22. M Diehl JH Risse K Brandt-Mainz M Dietlein KH Bohuslavizki P Matheja, et al. 2001 Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study Eur J Nucl Med 28 1671 1676 10.1007/s002590100614 1:CAS:528:DC%2BD3MXnvFGhsbc%3D 11702109 (Pubitemid 33036110)
23. S Szakall Jr O Esik G Bajzik I Repa G Dabasi I Sinkovics, et al. 2002 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma J Nucl Med 43 66 71 11801705
24. A Iagaru R Masamed PA Singer PS Conti 2007 Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT Mol Imaging Biol 9 72 77 10.1007/s11307-006-0072-1 17186139 (Pubitemid 46336221)
25. TJ Musholt PB Musholt F Dehdashti JF Moley 1997 Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study Surgery 122 1049 1060 10.1016/S0039-6060(97)90208-7 1:STN:280:DyaK1c%2FoslOquw%3D%3D 9426419 discussion 1060-1061 (Pubitemid 28016672)
26. M Van Essen EP Krenning M De Jong R Valkema DJ Kwekkeboom 2007 Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours Acta Oncol 46 723 734 10.1080/02841860701441848 17653893 (Pubitemid 47123757)
27. L Bodei D Handkiewicz-Junak C Grana C Mazzetta P Rocca M Bartolomei, et al. 2004 Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas Cancer Biother Radiopharm 19 65 71 10.1089/108497804773391694 1:CAS:528:DC%2BD2cXisFChs7o%3D 15068613 (Pubitemid 38352287)
28. C Waldherr T Schumacher M Pless A Crazzolara HR Maecke EU Nitzsche, et al. 2001 Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octrotide: a pilot study Nucl Med Commun 22 673 678 10.1097/00006231-200106000-00011 1:CAS:528:DC%2BD3MXkvFymtLc%3D 11403179 (Pubitemid 32525938)